Veru Advances Sabizabulin Phase 2 After Overcoming Resistance to RASONQUE
Veru will proceed with a Phase 2 trial for new metastatic pancreatic cancer research showing its drug overcomes resistance to Revolution Medicines' daraxonrasib, signaling a potential new market opportunity.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day